Skip to main content
RLMD logo

RLMD · Relmada Therapeutics, Inc.

Track RLMD — free
$2.94 +0.09 (+2.98%)
Market Cap
$304.61M
Shares
106.69M
Volume · Nov 19 197.91K Avg daily vol (3M) 1.41M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.86 Open$2.96 Day$2.85–3.09 52W close$2.86–7.86 Avg vol 30d1.7M Short int10.8M · 10.2% of shares · 6.4d Short vol50% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Up next

Mar 18, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 16
Investor event
NDV-1 bladder cancer trial planned; $202 million cash to 2029

Relmada Therapeutics plans a phase three trial of NDV-1, an extended-release form of gencitabine and docetaxel for bladder cancer. The company expects to enroll its first patient within Q1 if the IND clears in January-February. The company reported $202 million of cash and marketable securities, which it said takes it out through 2029.

6 source passages
And so NDV-1 is an extended release formulation of Gendosi. the NW1 is a standard-based formulation of two well-known chemotherapies for cancer, gencitabine and docetaxel So if we get the IND cleared in the January-February time frame, I would say within the Q1 we can enroll the first patient. So last week we reported $202 million of cash and marketable securities on the books. That will take us out through 2029. And the big catalysts are a completion of the phase three studies. Open the document at this passage
Nov 16
Current report 8-K
Jakobsen appointed to lead NDV-01 Phase 3 development

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology on November 16, 2026. He will lead clinical development across its pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.

Regulation FD disclosure
2 source passages
On November 16, 2026 Relmada Therapeutics, Inc. (the “Company”), issued a press release announcing the appointment of Jørn Skibsted Jakobsen, MD, PhD, as the Company’s Chief Development Officer. Dr. Jakobsen will lead clinical development across Relmada’s pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01. Open the document at this passage
Nov 12
Earnings call
NDV01 responses remained durable at 18 months

RealMata reported that 12 of 14 evaluable NDV01 patients remained in complete response at 18 months, including 7 of 8 BCG-unresponsive patients, plans IND submissions by year-end 2026, and holds $202.1 million funding operations through 2029.

5 source passages
Of the 14 evaluable patients at 18 months, 12 or 86% remain in CR. In the BCG unresponsive subgroup, 7 of 8 patients, or 88%, remain in CR at 18 months. We have made significant progress in the manufacturing process, and we are on track to submit the IND by year-end 2026. RealMata closed the third quarter of 2026 with cash, cash equivalents, and short-term investments of $202.1 million, compared to $93 million at December 31, 2025. Our current cash position is expected to fund company operations through 2029, including completion of the Registrational Phase III MDV01 Spectrum Studies. Open the document at this passage
Nov 12
Current report 8-K
Cash runway reaches 2029 as NDV-01 IND advances

Relmada Therapeutics, Inc. reported $202.1 million in cash, cash equivalents and short-term investments, expected to fund operations through 2029. NDV-01 and sepranolone IND submissions remain on track for year-end 2026.

Financial results, Regulation FD disclosure
4 source passages
Relmada Therapeutics, Inc. Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026, expected to fund operations through 2029 NDV-01 United States IND submission – By year-end 2026 Sepranolone United States IND submission – By year-end 2026 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widened while two IND filings are planned

Relmada Therapeutics reported a nine-month net loss of $45,828,300, versus $37,517,400. It plans U.S. IND filings for NDV-01 and sepranolone by year-end 2026 and says existing liquidity funds operations for at least 12 months.

Net loss $13.86M Diluted EPS -$0.12
Read from the MD&A section
4 source passages
The net loss for the Company for the nine months ended September 30, 2026 and 2025 was approximately $45,828,300 and $37,517,400 respectively. Relmada expects to file a United States IND application for NDV-01 with the FDA by year-end 2026. Relmada expects to file a United States IND application for sepranolone with the FDA by year-end 2026. the Company concluded the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these unaudited condensed consolidated financial statements. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$65.70M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$202.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+238.8%
Year over year · more shares
Price change (1Y)
-33.1%
Trailing year
Short interest
10.2%
Latest settlement · 6.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. NDV-01 delivered durable Phase 2 responses and favorable tolerability while remaining on track for a year-end 2026 IND submission, and $202.1 million of liquidity is expected to fund operations through 2029. The main negatives were two Month 15 progressions to muscle-invasive disease and higher operating cash use and net losses.

Bullish
  • + NDV-01 showed durable 18-month responses, with 86% of evaluable 12-month complete responders remaining in complete response.
  • + NDV-01's Phase 2 safety profile remained favorable, with no Grade ≥3 treatment-related adverse events, serious adverse events, or discontinuations.
  • + The NDV-01 CMC program remained on track for a year-end 2026 IND submission, with a manufacturing plan intended to supply the Phase 3 program through completion.
  • + The registrational Phase 3 program was renamed SPECTRUM.
  • + Cash, cash equivalents, and short-term investments totaled $202.1 million and were expected to fund operations through 2029.
  • + Updated 12-month Phase 2 results showed a 94% anytime complete-response rate, a 77% 12-month complete-response rate, and 100% progression-free and cystectomy-free survival through 12 months.
Bearish
  • − Two BCG-naïve patients with T1 disease progressed to muscle-invasive T2a disease at the Month 15 assessment.
  • − Third-quarter R&D expense increased to $9.2 million from $4.0 million, driven partly by study preparation, manufacturing, storage, and compensation costs.
  • − Third-quarter net cash used in operating activities rose to $12.6 million from $6.7 million.
  • − Third-quarter net loss widened to $13.9 million, or $0.12 per basic and diluted share, from $10.1 million, or $0.30 per share.
  • − Nine-month net cash used in operating activities increased to $37.3 million from $31.2 million.
  • − Nine-month net loss increased to $45.8 million, or $0.44 per basic and diluted share, from $37.5 million, or $1.16 per share.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −47%
below
Price vs 50-day avg −23%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −11%
trailing
6-month return −60%
trailing
YTD return −41%
this year
Relative strength −57%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$1.7M over 90 days · 0% sells
Short interest Falling
10.16% of shares out · ▼ -11.0% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
135 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Fair
Revenue growth −35%
Y/Y
Gross margin 21%
contracting
EPS growth +45%
Y/Y
Free cash flow $-45.8M
Balance sheet $3.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 94%
annualized · 1-yr
Max drawdown −64%
past year
ATR 12.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−47% Bearish
Price vs 50-day avg
−23% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$1.7M over 90 days · 0% sells
Short interest Falling
10.16% of shares out · ▼ -11.0% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
135 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $8
vs 200-day avg -47% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
12-month landmark CR 77% Month 12 —
Anytime CR 94% Interim P2 data —
BCG-unresponsive subgroup 12-month CR rate 73% Updated 12-month efficacy results —
BCG-unresponsive subgroup anytime CR rate 96% Updated 12-month efficacy results —
BCG-unresponsive subgroup evaluable patients who reached 18 months remained in CR 88% Initial 18-month durability results —
Cystectomy Free Survival 100% Month 12 —
evaluable patients who reached 18 months remained in CR 86% Initial 18-month durability results —
Grade ≥ 3 TR AEs & DCs 0% Interim P2 data —
patients in complete response (CR) at 12 months continued into the long-term extension (LTE) 23 Initial 18-month durability results —
Progression Free Survival 100% Month 12 —
Cash, cash equivalents, and short-term investments balance $217.7M As of June 30, 2026 —
Net cash used in operating activities $9.6M the three months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RLMD
Relmada Therapeutics, Inc.
this stock
$304.61M -40.9% -73.2% — 10.2%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
135
% held
97.8%
Net QoQ
+4.1M sh
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
112
View
Short & Settlement
Short Interest Falling
Shares short
10.8M
Days to cover
6.4d
Change
-1.3M sh
View
Short Volume
Short vol %
50%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
328.0K
Value
$1.0M
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
37.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$1.7M
Buyers / Sellers
2 / 0
Buyers Sellers
View
Congressional Trades Sell
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Revenue (FY)
$5.1K
Net income (FY)
$-57.4M
EPS diluted
$-1.45
View
Buybacks
Remaining
shares 4.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
20

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology on November 16, 2026. He will lead clinical development across its pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.

View
Proposed Sales
Value
$442.5K
Shares
75.0K
Filed
Feb 20, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Relmada Therapeutics Appoints Uro…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
RLMD -35.6% -11.1% -60.4% -20.3% -40.9%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -31.7% -5.5% -56.9% -16.9% -48.0%

Capital returns

Buyback program · as of Mar 10, 2014
Authorized
—
Spent (derived)
—
Remaining
shares 4.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1553643 CUSIP 75955J402 13F (30d) 150 filings 132 filers Visit website Investor relations